Anticancer evidence for zoledronic acid across the cancer continuum

Luis Costa, Peter Harper, Robert E. Coleman, Allan Lipton

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

Emerging evidence from clinical trials with zoledronic acid (ZOL) suggests that ZOL may have anticancer activity in a variety of cancer types. Retrospective studies and subset analyses as well as prospectively designed clinical trials have demonstrated that ZOL has survival benefits in patients with advanced cancers. Several studies have shown that ZOL improves disease-free survival, reduces the persistence of circulating and disseminated tumor cells, which are known to be predictive of disease recurrence, and decreases residual invasive tumor size in patients with early breast cancer. These data suggest that, in addition to providing skeletal-related event (SRE) benefits, ZOL also may potentially provide clinically meaningful benefits through anticancer activity. This article reviews the breadth of evidence supporting the anticancer activity of ZOL across the treatment continuum in patients with cancer.

Original languageEnglish (US)
JournalCritical Reviews in Oncology/Hematology
Volume77
Issue numberSUPPL.1
DOIs
StatePublished - Feb 1 2011

Fingerprint

zoledronic acid
Neoplasms
Clinical Trials
Circulating Neoplastic Cells
Residual Neoplasm
Disease-Free Survival
Retrospective Studies

All Science Journal Classification (ASJC) codes

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Costa, Luis ; Harper, Peter ; Coleman, Robert E. ; Lipton, Allan. / Anticancer evidence for zoledronic acid across the cancer continuum. In: Critical Reviews in Oncology/Hematology. 2011 ; Vol. 77, No. SUPPL.1.
@article{8b13c78d793a4505806f81d7bdb10257,
title = "Anticancer evidence for zoledronic acid across the cancer continuum",
abstract = "Emerging evidence from clinical trials with zoledronic acid (ZOL) suggests that ZOL may have anticancer activity in a variety of cancer types. Retrospective studies and subset analyses as well as prospectively designed clinical trials have demonstrated that ZOL has survival benefits in patients with advanced cancers. Several studies have shown that ZOL improves disease-free survival, reduces the persistence of circulating and disseminated tumor cells, which are known to be predictive of disease recurrence, and decreases residual invasive tumor size in patients with early breast cancer. These data suggest that, in addition to providing skeletal-related event (SRE) benefits, ZOL also may potentially provide clinically meaningful benefits through anticancer activity. This article reviews the breadth of evidence supporting the anticancer activity of ZOL across the treatment continuum in patients with cancer.",
author = "Luis Costa and Peter Harper and Coleman, {Robert E.} and Allan Lipton",
year = "2011",
month = "2",
day = "1",
doi = "10.1016/S1040-8428(11)70006-3",
language = "English (US)",
volume = "77",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "SUPPL.1",

}

Anticancer evidence for zoledronic acid across the cancer continuum. / Costa, Luis; Harper, Peter; Coleman, Robert E.; Lipton, Allan.

In: Critical Reviews in Oncology/Hematology, Vol. 77, No. SUPPL.1, 01.02.2011.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Anticancer evidence for zoledronic acid across the cancer continuum

AU - Costa, Luis

AU - Harper, Peter

AU - Coleman, Robert E.

AU - Lipton, Allan

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Emerging evidence from clinical trials with zoledronic acid (ZOL) suggests that ZOL may have anticancer activity in a variety of cancer types. Retrospective studies and subset analyses as well as prospectively designed clinical trials have demonstrated that ZOL has survival benefits in patients with advanced cancers. Several studies have shown that ZOL improves disease-free survival, reduces the persistence of circulating and disseminated tumor cells, which are known to be predictive of disease recurrence, and decreases residual invasive tumor size in patients with early breast cancer. These data suggest that, in addition to providing skeletal-related event (SRE) benefits, ZOL also may potentially provide clinically meaningful benefits through anticancer activity. This article reviews the breadth of evidence supporting the anticancer activity of ZOL across the treatment continuum in patients with cancer.

AB - Emerging evidence from clinical trials with zoledronic acid (ZOL) suggests that ZOL may have anticancer activity in a variety of cancer types. Retrospective studies and subset analyses as well as prospectively designed clinical trials have demonstrated that ZOL has survival benefits in patients with advanced cancers. Several studies have shown that ZOL improves disease-free survival, reduces the persistence of circulating and disseminated tumor cells, which are known to be predictive of disease recurrence, and decreases residual invasive tumor size in patients with early breast cancer. These data suggest that, in addition to providing skeletal-related event (SRE) benefits, ZOL also may potentially provide clinically meaningful benefits through anticancer activity. This article reviews the breadth of evidence supporting the anticancer activity of ZOL across the treatment continuum in patients with cancer.

UR - http://www.scopus.com/inward/record.url?scp=79951842507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951842507&partnerID=8YFLogxK

U2 - 10.1016/S1040-8428(11)70006-3

DO - 10.1016/S1040-8428(11)70006-3

M3 - Review article

VL - 77

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - SUPPL.1

ER -